December 08, 2022
Features
42
12
Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?
December 08, 2022
Features
42
12
Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.
December 08, 2022
Executive Profile
42
12
Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.
December 08, 2022
Finance
42
12
Will biopharma investment heat up and signal better fortunes for 2023?
December 08, 2022
Marketing
42
12
Whether pharma or FDA, healthcare outreach more visible than ever.
December 08, 2022
Leadership
42
12
Companies should search within to gain talent edge.
December 08, 2022
Europe Report
42
12
No shortage of views being expressed on drug shortages.
December 08, 2022
Washington Report
42
12
Year characterized by mix of key advances, contentious stances.
December 08, 2022
From the Editor
42
12
Experts in attendance at Pharma 2022 share insights on medical affairs.
December 08, 2022
Issue PDF
42
12
Click the title above for a link to open the Pharmaceutical Executive December 2022 issue in an interactive PDF format.
November 10, 2022
Back Page
42
12
Virtual audits proving to be beneficial post-COVID despite continuing challenges.